Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBT Margin: 2020-2025

Historic EBT Margin for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -243.13%.

  • Janux Therapeutics' EBT Margin rose 614844.00% to -243.13% in Q3 2025 from the same period last year, while for Sep 2025 it was -494.92%, marking a year-over-year decrease of 3101.00%. This contributed to the annual value of -651.62% for FY2024, which is 6956.00% up from last year.
  • Janux Therapeutics' EBT Margin amounted to -243.13% in Q3 2025, which was up 96.20% from -6,391.57% recorded in Q3 2024.
  • Janux Therapeutics' 5-year EBT Margin high stood at -66.98% for Q2 2024, and its period low was -6,391.57% during Q3 2024.
  • For the 3-year period, Janux Therapeutics' EBT Margin averaged around -1,415.85%, with its median value being -665.13% (2023).
  • As far as peak fluctuations go, Janux Therapeutics' EBT Margin tumbled by 593,198bps in 2024, and later skyrocketed by 614,844bps in 2025.
  • Over the past 5 years, Janux Therapeutics' EBT Margin (Quarterly) stood at -830.20% in 2021, then spiked by 26,552bps to -564.67% in 2022, then soared by 8,690bps to -477.77% in 2023, then tumbled by 593,198bps to -6,391.57% in 2024, then skyrocketed by 614,844bps to -243.13% in 2025.
  • Its last three reported values are -243.13% in Q3 2025, -6,391.57% for Q3 2024, and -66.98% during Q2 2024.